« Return to News | CROs/Service Providers

Harlan Laboratories expands facilities

Tuesday, May 14, 2013 01:33 PM

CRO Harlan Laboratories, which also provides research models, has expanded its specialty research production facilities in Indianapolis and Livermore, Calif. This expansion more than doubles the number of isolators at these sites, allowing Harlan to meet growing customer demand for its immunocompromised models.

"Our investment in these facilities underscores our commitment to providing the highest quality research models and services to investigators across the globe," said Joe Meyer , vice president, global commercial operations. "We will continue to expand and enhance our facilities worldwide to meet the needs of the research community in key therapeutic research areas like oncology, immunology and toxicology."

The facilities have environmentally controlled breeding isolators, supported by individual air supply and HEPA filtered air handling to ensure the integrity of the colony housed within each isolator. They also feature the latest equipment and biosecurity measures including a watering system with automatic flushing to help prevent the unwanted proliferation of organisms, as well as a whole building redundant backup power system. Harlan also incorporated several sustainable components to the newly renovated Indianapolis and Livermore facilities.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.